ACAziz Chouchane

Aziz Chouchane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aziz Chouchane has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Parathyroid Carcinoma Mimicking a Parathyroid Adenoma on [18F]F-Choline-PET With Occult Metastases

    by Carola M. Bregenzer, Roman Trepp, Florian Dammann, Reto M. Kaderli, Aziz Chouchane, Robert Seifert

    An 80-year-old man with hypercalcemia and hyperparathyroidism was suspected of having a parathyroid adenoma, which was localized on [ 18 F]F-choline-PET/CT. Still, after surgical removal of the suspected adenoma with an intraoperative parathyroid hormone decrease of >50%, severe hypercalcemia recurred quickly. A repeated [ 18 F]F-choline-PET/CT raised suspicion of a single contralateral parathyroid adenoma or multiglandular disease. Given the inconclusive findings, a histological reassessment of the suspected parathyroid adenoma showed the presence of a singular vessel invasion, which alerted the diagnosis to parathyroid carcinoma. An additionally performed [ 18 F]FDG-PET/CT revealed a liver lesion and MRI confirmed multiple liver metastases, which could not be seen on [ 18 F]F-choline-PET/CT.

  • Open Access

    Correction to: Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1/DAXX/ATRX Explain Biological Variability

    by Simona Avanthay, Annunziata Di Domenico, Philipp Kirchner, Konstantin Bräutigam, Aziz Chouchane, Renaud Maire, Christina Thirlwell, Corina Kim-Fuchs, Aurel Perren, Ilaria Marinoni

  • Open Access

    Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1/DAXX/ATRX Explain Biological Variability

    by Simona Avanthay, Annunziata Di Domenico, Philipp Kirchner, Konstantin Bräutigam, Aziz Chouchane, Renaud Maire, Christina Thirlwell, Corina Kim-Fuchs, Aurel Perren, Ilaria Marinoni

    About 40% of non-functioning (NF) Pancreatic Neuroendocrine Tumors (PanNETs) harbour mutations in MEN1 , often co-occurring with DAXX/ATRX. While the ADM group ( MEN1 and DAXX/ATRX co-mutated) exhibits homogeneous genetic and epigenetic features and a consistent risk of relapse, it shows considerable variability in treatment response, suggesting an underlying molecular diversity. In this study we aimed to elucidate the molecular mechanisms underlying this heterogeneity of ADM PanNETs by integrating transcriptomic ( n = 36) and DNA methylation ( n = 93) data. First, DNA methylation discriminates ADM-PanNET from PanNET mutated only in MEN1 (α-like), revealing enhancer, peri-centromeric, and telomeric methylation changes associated with alternative lengthening of telomeres and increased chromosomal instability. Transcriptomic analysis further revealed three distinct ADM subtypes: ADM hypoxic, ADM NST (No Special Type), and ADM immunosuppressive. The ADM hypoxic subtype is characterized by strong hypoxia signature, likely regulated epigenetically. The ADM NST subtype appears to be primarily driven by epigenetic changes that promote proliferation. Notably, the ADM immunosuppressive subtype, although significantly smaller (< 2.5 cm, p = 0.023), exhibits strong immune and metastasis-like signatures, suggesting a uniquely aggressive biology despite its reduced size. By defining these three novel ADM subtypes, our study provides a refined framework for understanding PanNET heterogeneity. This classification underscores potential diagnostic markers and highlights distinct biological vulnerabilities that may inform the development of subtype-tailored therapeutic strategies.


  • Open Access

    Neuroendokrine Neoplasien

    by Aziz Chouchane, Konstantin Bräutigam, Aurel Perren

    Zusammenfassung: Neuroendokrine Tumoren (NET) sind eine bunte Gruppe von Neoplasien, die von neuroendokrinen Zellen im gesamten Körper ausgehen. Die NET-Diagnose stellt aufgrund ihrer vielfältigen Erscheinungsformen, Morphologie und biologischen Verhaltensweisen eine besondere Herausforderung dar. Dieser Artikel bietet einen Überblick über die wichtigsten für Allgemeinpathologen relevanten diagnostischen Prinzipien, und betont die Bedeutung eines multidisziplinären Ansatzes, der klinische, radiologische, histopathologische und immunhistochemische Daten integriert. Die Etablierung neuer Marker sowie jüngste Fortschritte in der molekularen Pathologie und die Anwendung von Klassifizierungssystemen werden erörtert, wobei deren Einfluss auf die Prognose und therapeutische Strategien hervorgehoben wird.


  • Open Access

    Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies

    by Simon L. April-Monn, Philipp Kirchner, Katharina Detjen, Konstantin Bräutigam, Mafalda A. Trippel, Tobias Grob, Cyril Statzer, Renaud S. Maire, Attila Kollàr, Aziz Chouchane, et al.

    There are no therapeutic predictive biomarkers or representative preclinical models for high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), a highly aggressive, fatal, and heterogeneous malignancy. We established patient-derived (PD) tumoroids from biobanked tissue samples of advanced high-grade GEP-NEN patients and applied this model for targeted rapid ex vivo pharmacotyping, next-generation sequencing, and perturbational profiling. We used tissue-matched PD tumoroids to profile individual patients, compared ex vivo drug response to patients’ clinical response to chemotherapy, and investigated treatment-induced adaptive stress responses.PD tumoroids recapitulated biological key features of high-grade GEP-NEN and mimicked clinical response to cisplatin and temozolomide ex vivo. When we investigated treatment-induced adaptive stress responses in PD tumoroids in silico, we discovered and functionally validated Lysine demethylase 5 A and interferon-beta, which act synergistically in combination with cisplatin. Since ex vivo drug response in PD tumoroids matched clinical patient responses to standard-of-care chemotherapeutics for GEP-NEN, our rapid and functional precision oncology approach could expand personalized therapeutic options for patients with advanced high-grade GEP-NEN.